Call for papers - Emerging therapies for prostate cancer

Guest Editors

Arjun Pon Avudaiappan, MD, Miami Cancer Institute, USA
David J. Benjamin, MD, Hoag Family Cancer Institute, USA
Fabrizio Presicce, MD, PhD, San Filippo Neri Hospital, Italy

Submission Status: Open | Submission Deadline: 16 February 2026

BMC Urology is calling for submissions to our Collection on Emerging therapies for prostate cancer.

This Collection invites research contributions on emerging therapies for prostate cancer, focusing on innovative treatment modalities such as immunotherapy, targeted therapy, and genetic profiling. We aim to showcase studies that examine clinical trials, patient outcomes, and the management of side effects to enhance therapeutic approaches and improve the quality of life for patients diagnosed with prostate cancer.

New Content Item This Collection supports and amplifies research related to SDG 3: Good Health and Well-being.

Submit to Collection

Meet the Guest Editors

Back to top

Arjun Pon Avudaiappan, MD, Miami Cancer Institute, USA

Dr Arjun Pon Avudaiappan is a urologist with a decade of experience. Currently, he is a research fellow at Miami Cancer Institute, Baptist Health South Florida, focused on research in uro-oncology. After completing his Urology residency in India, he pursued advanced laparoscopic urology and Vattikuti robotic uro-oncology fellowships. As a consultant urologist in India, he guided and mentored urology and general surgery residents, urophysicians, and undergraduate medical students. His research primarily focuses on uro-oncology and endourology. He has published papers in many peer-reviewed journals and presented at the American Urological Association, European Association of Urology, and various international conferences. He is currently researching the outcomes of different treatment modalities in genitourinary malignancies. With the increase in global life expectancy and an aging population, he is studying the effects of treatment outcomes within this demographic. He also investigates various diagnostic modalities and organ-preservation strategies in bladder, kidney, prostate, and penile cancers to improve the diagnostic, oncological, and functional outcomes.

David J. Benjamin, MD, Hoag Family Cancer Institute, USA

Dr David J. Benjamin is a genitourinary medical oncologist at Hoag Family Cancer Institute. He has co-authored over 70 publications in leading medical journals. He has presented his research at several national and international conferences. He has been recognized for his excellence in clinical/translational research, receiving the 2022 Genitourinary Cancers Symposium Merit Award from Conquer Cancer, the ASCO Foundation, as well as the 2022 UCI School of Medicine Outstanding Fellow/Resident Research Award. Dr Benjamin is a member of the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO). He is an editorial board member for ESMO Rare Cancers.

Fabrizio Presicce, MD, PhD, San Filippo Neri Hospital, Italy

Dr Fabrizio Presicce is a Specialist in Urology. He graduated with honors in Medicine and Surgery in 2010 from the Università Cattolica del Sacro Cuore in Rome. He began his specialist training in Urology at the Department of Urology, Sant'Andrea Hospital, Sapienza University of Rome. In 2015, he spent a six-month training abroad at the Royal Hallamshire Hospital in Sheffield, an international center of excellence for urological diseases. The same year, he was selected as the European representative for the prestigious USANZ trainee week in Brisbane. Dr Presicce completed his residency and earned a PhD with honors in Advanced technologies in surgery both at Sapienza University of Rome. He completed a second-level university master’s degree in laparoscopic and robotic urological surgery with honors at the same institution. He is a Medical Officer in Urology at San Filippo Neri Hospital in Rome. In 2023, he obtained the National Scientific Qualification as Associate Professor in the academic discipline 06/E2 – plastic-reconstructive surgery, pediatric surgery, and urology and received certification to use the Da Vinci robotic platform as a console surgeon (Primary Operator). That same year, he was selected by the Italian Society of Urology for the SIU ROB-IT robotic surgery project. Dr Presicce is a passionate researcher in all areas of urological pathology, particularly interested in diagnosing and treating benign prostatic hyperplasia, uro-oncology, and urinary stone disease. He is actively involved in numerous clinical studies on the diagnosis and treatment of prostate cancer and the management of lower urinary tract symptoms/benign prostatic hyperplasia. In recent years, he has focused primarily on minimally invasive robotic urological surgery, especially assessing the impact of these techniques on oncological and functional outcomes. Dr Presicce has published 38 articles in international scientific journals and has a personal Impact Factor 15. In addition, he is an active reviewer for more than 20 international peer-reviewed journals. He is a member of the Italian Society of Urology (SIU) and the European Association of Urology (EAU). He serves on BMC Urology, Current Urology, and Minerva Urology and Nephrology editorial boards.

About the Collection

BMC Urology is calling for submissions to our Collection on Emerging therapies for prostate cancer.

Prostate cancer remains one of the most prevalent malignancies among men worldwide, necessitating ongoing research into innovative therapeutic approaches. This Collection aims to explore emerging therapies that have the potential to enhance treatment outcomes for patients with prostate cancer. Current treatment modalities, including surgery, radiation, and traditional hormone therapies, have made significant strides; however, there is a pressing need to investigate novel strategies such as immunotherapy, targeted therapy, and genetic profiling to improve efficacy and reduce side effects.

Advancements in the understanding of prostate cancer biology have paved the way for promising therapies that target specific genetic and molecular pathways. Recent developments in immunotherapy and targeted therapies have shown potential in clinical trials, leading to improved patient outcomes and survival rates. By focusing on personalized treatment approaches, researchers are beginning to unravel the complexities of prostate cancer, which may ultimately lead to more effective and tailored therapies that address the unique needs of individual patients.

As research in this field progresses, we anticipate significant breakthroughs that could revolutionize the landscape of prostate cancer treatment. Enhanced genetic profiling techniques may allow for even more precise targeting of therapies, minimizing adverse effects and maximizing therapeutic benefits. The integration of real-time monitoring and adaptive treatment strategies could also emerge, offering a more dynamic approach to patient care and improving overall survival rates in prostate cancer patients.

Advances in immunotherapy for prostate cancer
Targeted therapies and their effectiveness
The role of genetic profiling in treatment
Clinical trials and emerging treatment options
Assessing side effects and patient outcomes

This Collection supports and amplifies research related to SDG 3: Good Health and Well-being.

All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.

There are currently no articles in this collection.

Submission Guidelines

Back to top

This Collection welcomes submission of original Research Articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Emerging therapies for prostate cancer" from the dropdown menu.

All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.